Does percutaneous left atrial appendage transcatheter occlusion prevent stroke in high-risk patients with atrial fibrillation?
Transcatheter closure of the left atrial appendage is a feasible novel implant technology for patients with atrial fibrillation who are unsuitable for anticoagulation.
Thus, transcatheter closure of the LAA is feasible in humans. This novel implant technology may be appropriate for patients with AF who are not suitable candidates for anticoagulation therapy. Further trials are needed to show the long-term safety and its efficacy in reducing stroke.
Sievert et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: